# Official Journal C 126/2022

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 126 |
| | |
| English edition | Information and Notices | Volume 6521 March 2022 |

ISSN 1977-091X

Official Journal

of the European Union

C 126

English edition

Information and Notices

Volume 6521 March 2022

---

| Contents | page |
| --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2022/C 126/01 | Commission Notice on withdrawal periods in case of veterinary treatments of organic terrestrial livestock with veterinary medicinal products – RIPAC NOTE N° 2022-XX | 1 |
| 2022/C 126/02 | Non-opposition to a notified concentration (Case M.10614 – PAI PARTNERS / UVESCO) (
  1
  ) | 5 |
| 2022/C 126/03 | Non-opposition to a notified concentration (Case M.10456 – SKY / VIACOMCBS / JV) (
  1
  ) | 6 |
| 2022/C 126/04 | Non-opposition to a notified concentration (Case M.10153 – ORANGE / TELEKOM ROMANIA COMMUNICATIONS) (
  1
  ) | 7 |

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2022/C 126/01

Commission Notice on withdrawal periods in case of veterinary treatments of organic terrestrial livestock with veterinary medicinal products – RIPAC NOTE N° 2022-XX

1

2022/C 126/02

Non-opposition to a notified concentration (Case M.10614 – PAI PARTNERS / UVESCO) (
  1
  )

1

5

2022/C 126/03

Non-opposition to a notified concentration (Case M.10456 – SKY / VIACOMCBS / JV) (
  1
  )

1

6

2022/C 126/04

Non-opposition to a notified concentration (Case M.10153 – ORANGE / TELEKOM ROMANIA COMMUNICATIONS) (
  1
  )

1

7

---

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2022/C 126/05 | Euro exchange rates — 18 March 2022 | 8 |
| 2022/C 126/06 | Commission notice on current State aid recovery interest rates and reference/discount rates applicable as from 1 April 2022
  (Published in accordance with Article 10 of Commission Regulation (EC) No 794/2004
  ) | 9 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2022/C 126/05

Euro exchange rates — 18 March 2022

8

2022/C 126/06

Commission notice on current State aid recovery interest rates and reference/discount rates applicable as from 1 April 2022
  (Published in accordance with Article 10 of Commission Regulation (EC) No 794/2004
  )

(Published in accordance with Article 10 of Commission Regulation (EC) No 794/2004

)

9

---

| | |
| --- | --- |
| | (1)   Text with EEA relevance. |

---

(1)   Text with EEA relevance.

1

| EN | |
| --- | --- |

EN

---

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 21.3.2022 | EN | Official Journal of the European Union | C 126/1 |
| --- | --- | --- | --- |

21.3.2022

EN

Official Journal of the European Union

C 126/1

---

Commission Notice

on withdrawal periods in case of veterinary treatments of organic terrestrial livestock with veterinary medicinal products

(2022/C 126/01)

RIPAC (1) NOTE N° 2022-XX

| The present document is provided for information purposes only and its contents are not intended to replace consultation of any applicable legal sources or the necessary advice of a legal expert, where appropriate.


  Neither the Commission nor any person acting on its behalf can be held responsible for the use made of these notes nor can they be considered as a binding interpretation of the legislation.


  This document is intended to assist businesses and national authorities in the application of the European legislation. Only the Court of Justice of the European Union is competent to authoritatively interpret Union law. |
| --- |

The present document is provided for information purposes only and its contents are not intended to replace consultation of any applicable legal sources or the necessary advice of a legal expert, where appropriate.

Neither the Commission nor any person acting on its behalf can be held responsible for the use made of these notes nor can they be considered as a binding interpretation of the legislation.

This document is intended to assist businesses and national authorities in the application of the European legislation. Only the Court of Justice of the European Union is competent to authoritatively interpret Union law.

| SECTOR: | ORGANIC FARMING |
| --- | --- |
| | |
| MEASURE: | VETERINARY TREATMENTS for LIVESTOCK |
| | |
| SUBJECT: | WITHDRAWAL PERIODS - VETERINARY MEDICINAL PRODUCTS |
| | |
| PROVISIONS CONCERNED: | Regulation (EU) 2018/848 (2) - Annex II Part II points 1.5.1.2, 1.5.1.3, 1.5.2.5 and Regulation (EU) 2019/6 (3) – Articles 4, point (34), 106, 113 and 115 |

SECTOR:

ORGANIC FARMING

MEASURE:

VETERINARY TREATMENTS for LIVESTOCK

SUBJECT:

WITHDRAWAL PERIODS - VETERINARY MEDICINAL PRODUCTS

PROVISIONS CONCERNED:

Regulation (EU) 2018/848 (2) - Annex II Part II points 1.5.1.2, 1.5.1.3, 1.5.2.5 and Regulation (EU) 2019/6 (3) – Articles 4, point (34), 106, 113 and 115

Question 1: Should ‘vaccines’ be considered ‘chemically synthetised veterinary medicinal products’ as referred to in point 1.5.2.5 of Part II of Annex II to Regulation (EU) 2018/848?

Regulation (EU) 2018/848 applies from 1 January 2022, as established in Article 61 thereof.

Part II of Annex II to Regulation (EU) 2018/848 sets livestock production rules.

Point 1.5.2.5 of Part II of Annex II to Regulation (EU) 2018/848 states that ‘the withdrawal period between the last administration to an animal of a chemically synthetised allopathic veterinary medicinal product, including of an antibiotic, under normal conditions of use, and the production of organically produced foodstuffs from that animal shall be twice the withdrawal period referred to in Article 11 of Directive 2001/82/EC (4), and shall be at least 48 hours.’

Points 1.5.1.2 and 1.5.1.3 of Part II of Annex II to Regulation (EU) 2018/848 state respectively the following in relation to disease prevention for livestock: ‘immunological veterinary medicinal products may be used’, and ‘chemically synthetised allopathic veterinary medicinal products , including antibiotics and boluses of synthetised allopathic molecules, shall not be used for preventive treatments’. This establishes an implicit distinction between immunological veterinary medicinal products and chemically synthetised allopathic veterinary medicinal products.

Vaccines are immunological veterinary medicinal products and point 1.5.2.5 of Part II of Annex II to Regulation (EU) 2018/848 is not relevant for their use.

Question 2: When an organic terrestrial food-producing species of animal is treated with a veterinary medicinal product used in accordance with the terms of the marketing authorisation for that species, which withdrawal period should be applied between the last administration of a chemically synthetised allopathic veterinary medicinal product, including of an antibiotic, under normal conditions of use, and the production of organically produced foodstuffs from that animal?

Answer:

Regulation (EU) 2018/848 applies from 1 January 2022, as established in Article 61 thereof. Recital (43) of Regulation (EU) 2018/848, describes the intention of the legislator regarding the withdrawal period for animals and states that ‘animal health management should mainly be based on the prevention of disease. [...] The preventive use of chemically synthetised allopathic medicinal products, including antibiotics, should not be permitted in organic production. In the event of sickness or injury of an animal requiring immediate treatment, the use of such products should be limited to the minimum necessary to re-establish the well-being of the animal. In such cases, in order to guarantee the integrity of organic production for consumers, the official withdrawal period after use of such medicinal products as specified in the relevant Union legislation should be double the normal withdrawal period and have a minimum duration of 48 hours.’

Part II of Annex II to Regulation (EU) 2018/848 sets livestock production rules; livestock production is defined in Article 3, point (27), as meaning the production of domestic or domesticated terrestrial animals, including insects.

Point 1.5.2.5 of Part II of Annex II to Regulation (EU) 2018/848 applies. This provision states that ‘the withdrawal period between the last administration to an animal of a chemically synthetised allopathic veterinary medicinal product, including of an antibiotic, under normal conditions of use, and the production of organically produced foodstuffs from that animal shall be twice the withdrawal period referred to in Article 11 of Directive 2001/82/EC (5), and shall be at least 48 hours.’

The cross-reference to Article 11 of Directive 2001/82/EC in Regulation (EU) 2018/848 refers in particular to the second indent of paragraph 2 of that article, which states that ‘[...] unless the medicinal product used indicates a withdrawal period for the species concerned, the specified withdrawal period shall not be less than: — 7 days for eggs, — 7 days for milk, — 28 days for meat from poultry and mammals including fat and offal’ and should be interpreted as a reference to withdrawal periods of veterinary medicinal products used within or outside the terms of the marketing authorisation.

Hence, when an organic terrestrial food-producing species of animal is treated with a veterinary medicinal product used in accordance with the terms of the marketing authorisation for that species, the withdrawal period that applies to the production of organically produced foodstuffs from that animal is twice the withdrawal period set for that species of terrestrial food producing animal in the summary of the characteristics of the marketing authorisation of such a veterinary medicinal product and at least 48 hours.

In the particular case where the withdrawal period for a species of terrestrial food-producing animal laid down in the summary of the characteristics of the marketing authorisation of a veterinary medicinal product is zero days, it should be 48 hours in organic production.

From 28 January 2022, Regulation (EU) 2019/6 on veterinary medicinal products and repealing Directive 2001/82/EC will apply in combination with the specific provisions related to organic production of Regulation (EU) 2018/848 and the situation will remain the same as described above.

Question 3: When an organic terrestrial food-producing animal belonging to a certain species is treated with a veterinary medicinal product used outside the terms of the marketing authorisation for that species, which withdrawal period should be applied between the last administration of a chemically synthetised allopathic veterinary medicinal product, including of an antibiotic, under normal conditions of use, and the production of organically produced foodstuffs from that animal?

In case an organic terrestrial food-producing animal belonging to a certain species is treated with a veterinary medicinal product used outside the terms of the marketing authorisation for that species, between 1 January 2022 and 27 January 2022, the specified withdrawal period shall not be less than: — 14 days for eggs, — 14 days for milk, — 56 days for meat from poultry and mammals including fat and offal, which correspond to not less than twice the withdrawal periods set for conventional food producing animal species in Article 11 of Directive 2001/82/EC.

From 28 January 2022, Regulation (EU) 2019/6 on veterinary medicinal products and repealing Directive 2001/82/EC will apply in combination with the specific provisions related to organic production of Regulation (EU) 2018/848.

Articles 113 and 115 of Regulation (EU) 2019/6 set respectively the rules applying for the use of medicinal products outside the terms of the marketing authorisation in food-producing terrestrial animal species, and for the withdrawal period for medicinal products used outside the terms of the marketing authorisation in food producing animal species.

In particular, Article 115 states that:

‘unless a medicinal product used has a withdrawal period provided in its summary of the product characteristics for the animal species in question, a withdrawal period shall be set by the veterinarian in accordance with the following criteria:

| (a) | for meat and offal from food-producing mammals and poultry and farmed game birds the withdrawal period shall not be less than:






  (i) | the longest withdrawal period provided in its summary of the product characteristics for meat and offal multiplied by factor 1,5; |
| --- | --- | --- |

(a)

for meat and offal from food-producing mammals and poultry and farmed game birds the withdrawal period shall not be less than:

(i)

the longest withdrawal period provided in its summary of the product characteristics for meat and offal multiplied by factor 1,5;

| (ii) | 28 days if the medicinal product is not authorised for food-producing animals; |
| --- | --- |

(ii)

28 days if the medicinal product is not authorised for food-producing animals;

| (iii) | one day, if the medicinal product has a zero withdrawal period and is used in a different taxonomic family than the target species authorised; |
| --- | --- |

(iii)

one day, if the medicinal product has a zero withdrawal period and is used in a different taxonomic family than the target species authorised;

| (b) | for milk from animals producing milk for human consumption the withdrawal period shall not be less than:






  (i) | the longest withdrawal period for milk provided in the summary of the product characteristics for any animal species multiplied by factor 1,5; |
| --- | --- | --- |

(b)

for milk from animals producing milk for human consumption the withdrawal period shall not be less than:

(i)

the longest withdrawal period for milk provided in the summary of the product characteristics for any animal species multiplied by factor 1,5;

| (ii) | seven days, if the medicinal product is not authorised for animals producing milk for human consumption; |
| --- | --- |

(ii)

seven days, if the medicinal product is not authorised for animals producing milk for human consumption;

| (iii) | one day, if the medicinal product has a zero withdrawal period; |
| --- | --- |

(iii)

one day, if the medicinal product has a zero withdrawal period;

| (c) | for eggs from animals producing eggs for human consumption the withdrawal period shall not be less than:






  (i) | the longest withdrawal period for eggs provided in the summary of the product characteristics for any animal species multiplied by factor 1,5; |
| --- | --- | --- |

(c)

for eggs from animals producing eggs for human consumption the withdrawal period shall not be less than:

(i)

the longest withdrawal period for eggs provided in the summary of the product characteristics for any animal species multiplied by factor 1,5;

| (ii) | 10 days, if the product is not authorised for animals producing eggs for human consumption; |
| --- | --- |

(ii)

10 days, if the product is not authorised for animals producing eggs for human consumption;

| 2. | If the calculation of the withdrawal period according to points (a)(i), (b)(i), (c)(i), (d)(i) and (ii) of paragraph 1 results in a fraction of days, the withdrawal period shall be rounded up to the nearest number of days. |
| --- | --- |

2.

If the calculation of the withdrawal period according to points (a)(i), (b)(i), (c)(i), (d)(i) and (ii) of paragraph 1 results in a fraction of days, the withdrawal period shall be rounded up to the nearest number of days.

| 4. | For bees, the veterinarian shall determine the appropriate withdrawal period by assessing the specific situation of the particular beehive or beehives on a case-by-case basis and in particular the risk of residue in honey or in any other foodstuffs harvested from beehives intended for human consumption. |
| --- | --- |

4.

For bees, the veterinarian shall determine the appropriate withdrawal period by assessing the specific situation of the particular beehive or beehives on a case-by-case basis and in particular the risk of residue in honey or in any other foodstuffs harvested from beehives intended for human consumption.

| 5. | By way of derogation from Article 113(1) and (4), the Commission shall, by means of implementing acts, establish a list of substances which are essential for the treatment of equine species, or which bring added clinical benefit compared to other treatment options available for equine species and for which the withdrawal period for equine species shall be six months. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 145(2).’ |
| --- | --- |

5.

By way of derogation from Article 113(1) and (4), the Commission shall, by means of implementing acts, establish a list of substances which are essential for the treatment of equine species, or which bring added clinical benefit compared to other treatment options available for equine species and for which the withdrawal period for equine species shall be six months. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 145(2).’

Hence, from 28 January 2022, if an organic terrestrial food-producing animal belonging to a certain species is treated with a veterinary medicinal product used outside the terms of the marketing authorisation for that species, the withdrawal period that should be applied between the last administration of a chemically synthetised allopathic veterinary medicinal product, including of an antibiotic, under normal conditions of use, and the production of organically produced foodstuffs from that animal should be twice the relevant withdrawal period set out in Article 115(1) of Regulation (EU) 2019/6 and at least 48 hours.

---

(1)  RIPAC (named after its French acronym Registre d’ Interprétation de la Politique Agricole Commune) is a register and database of interpretative notes on agricultural law.

(2)  Regulation (EU) 2018/848 of the European Parliament and of the Council of 30 May 2018 on organic production and labelling of organic products and repealing Council Regulation (EC) No 834/2007 (OJ L 150, 14.6.2018, p. 1).

(3)  Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 43).

(4)  Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (OJ L 311, 28.11.2001, p. 1 which will be repealed by Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 4).

(5)  Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (OJ L 311, 28.11.2001, p. 1 which will be repealed by Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 4).

---

| 21.3.2022 | EN | Official Journal of the European Union | C 126/5 |
| --- | --- | --- | --- |

21.3.2022

EN

Official Journal of the European Union

C 126/5

---

Non-opposition to a notified concentration

(Case M.10614 – PAI PARTNERS / UVESCO)

(Text with EEA relevance)

(2022/C 126/02)

On 14 March 2022, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10614. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32022M10614. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 21.3.2022 | EN | Official Journal of the European Union | C 126/6 |
| --- | --- | --- | --- |

21.3.2022

EN

Official Journal of the European Union

C 126/6

---

Non-opposition to a notified concentration

(Case M.10456 – SKY / VIACOMCBS / JV)

(Text with EEA relevance)

(2022/C 126/03)

On 1 December 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10456. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10456. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 21.3.2022 | EN | Official Journal of the European Union | C 126/7 |
| --- | --- | --- | --- |

21.3.2022

EN

Official Journal of the European Union

C 126/7

---

Non-opposition to a notified concentration

(Case M.10153 – ORANGE / TELEKOM ROMANIA COMMUNICATIONS)

(Text with EEA relevance)

(2022/C 126/04)

On 28 July 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) in conjunction with Article 6(2) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10153. EUR-Lex is the online point of access to European Union law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10153. EUR-Lex is the online point of access to European Union law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 21.3.2022 | EN | Official Journal of the European Union | C 126/8 |
| --- | --- | --- | --- |

21.3.2022

EN

Official Journal of the European Union

C 126/8

---

Euro exchange rates (1)

18 March 2022

(2022/C 126/05)

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,1008 |
| JPY | Japanese yen | 131,40 |
| DKK | Danish krone | 7,4423 |
| GBP | Pound sterling | 0,83925 |
| SEK | Swedish krona | 10,4303 |
| CHF | Swiss franc | 1,0314 |
| ISK | Iceland króna | 142,90 |
| NOK | Norwegian krone | 9,6940 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 24,837 |
| HUF | Hungarian forint | 375,33 |
| PLN | Polish zloty | 4,7135 |
| RON | Romanian leu | 4,9483 |
| TRY | Turkish lira | 16,3054 |
| AUD | Australian dollar | 1,4945 |
| CAD | Canadian dollar | 1,3911 |
| HKD | Hong Kong dollar | 8,6101 |
| NZD | New Zealand dollar | 1,6026 |
| SGD | Singapore dollar | 1,4952 |
| KRW | South Korean won | 1 337,31 |
| ZAR | South African rand | 16,5347 |
| CNY | Chinese yuan renminbi | 7,0031 |
| HRK | Croatian kuna | 7,5685 |
| IDR | Indonesian rupiah | 15 782,11 |
| MYR | Malaysian ringgit | 4,6157 |
| PHP | Philippine peso | 57,622 |
| RUB | Russian rouble | |
| THB | Thai baht | 36,745 |
| BRL | Brazilian real | 5,5784 |
| MXN | Mexican peso | 22,5905 |
| INR | Indian rupee | 83,7825 |

Currency

Exchange rate

USD

US dollar

1,1008

JPY

Japanese yen

131,40

DKK

Danish krone

7,4423

GBP

Pound sterling

0,83925

SEK

Swedish krona

10,4303

CHF

Swiss franc

1,0314

ISK

Iceland króna

142,90

NOK

Norwegian krone

9,6940

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

24,837

HUF

Hungarian forint

375,33

PLN

Polish zloty

4,7135

RON

Romanian leu

4,9483

TRY

Turkish lira

16,3054

AUD

Australian dollar

1,4945

CAD

Canadian dollar

1,3911

HKD

Hong Kong dollar

8,6101

NZD

New Zealand dollar

1,6026

SGD

Singapore dollar

1,4952

KRW

South Korean won

1 337,31

ZAR

South African rand

16,5347

CNY

Chinese yuan renminbi

7,0031

HRK

Croatian kuna

7,5685

IDR

Indonesian rupiah

15 782,11

MYR

Malaysian ringgit

4,6157

PHP

Philippine peso

57,622

RUB

Russian rouble

THB

Thai baht

36,745

BRL

Brazilian real

5,5784

MXN

Mexican peso

22,5905

INR

Indian rupee

83,7825

---

(1)  Source: reference exchange rate published by the ECB.

---

| 21.3.2022 | EN | Official Journal of the European Union | C 126/9 |
| --- | --- | --- | --- |

21.3.2022

EN

Official Journal of the European Union

C 126/9

---

Commission notice on current State aid recovery interest rates and reference/discount rates applicable as from 1 April 2022

(Published in accordance with Article 10 of Commission Regulation (EC) No 794/2004 (1)
  )

(2022/C 126/06)

Base rates calculated in accordance with the Communication from the Commission on the revision of the method for setting the reference and discount rates (OJ C 14, 19.1.2008, p. 6.). Depending on the use of the reference rate, the appropriate margins have still to be added as defined in this communication. For the discount rate this means that a margin of 100 basispoints has to be added. The Commission Regulation (EC) No 271/2008 of 30 January 2008 amending Regulation (EC) No 794/2004 foresees that, unless otherwise provided for in a specific decision, the recovery rate will also be calculated by adding 100 basispoints to the base rate.

Modified rates are indicated in bold.

Previous table published in OJ C 76, 17.2.2022, p. 4.

| From | To | AT | BE | BG | CY | CZ | DE | DK | EE | EL | ES | FI | FR | HR | HU | IE | IT | LT | LU | LV | MT | NL | PL | PT | RO | SE | SI | SK | UK |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1.4.2022 | ... | -0,49 | -0,49 | 0,00 | -0,49 | 4,00 | -0,49 | 0,00 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | 0,26 | 4,66 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | 3,42 | -0,49 | 3,38 | -0,01 | -0,49 | -0,49 | 0,66 |
| 1.3.2022 | 31.3.2022 | -0,49 | -0,49 | 0,00 | -0,49 | 4,00 | -0,49 | -0,03 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | 0,26 | 4,02 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | 2,85 | -0,49 | 2,74 | -0,04 | -0,49 | -0,49 | 0,66 |
| 1.2.2022 | 28.2.2022 | -0,49 | -0,49 | 0,00 | -0,49 | 3,29 | -0,49 | -0,03 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | 0,26 | 3,17 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | 2,04 | -0,49 | 2,74 | -0,05 | -0,49 | -0,49 | 0,66 |
| 1.1.2022 | 31.1.2022 | -0,49 | -0,49 | 0,00 | -0,49 | 2,49 | -0,49 | -0,01 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | 0,26 | 2,38 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | -0,49 | 1,21 | -0,49 | 2,27 | -0,03 | -0,49 | -0,49 | 0,51 |

From

To

AT

BE

BG

CY

CZ

DE

DK

EE

EL

ES

FI

FR

HR

HU

IE

IT

LT

LU

LV

MT

NL

PL

PT

RO

SE

SI

SK

UK

1.4.2022

...

-0,49

-0,49

0,00

-0,49

4,00

-0,49

0,00

-0,49

-0,49

-0,49

-0,49

-0,49

0,26

4,66

-0,49

-0,49

-0,49

-0,49

-0,49

-0,49

-0,49

3,42

-0,49

3,38

-0,01

-0,49

-0,49

0,66

1.3.2022

31.3.2022

-0,49

-0,49

0,00

-0,49

4,00

-0,49

-0,03

-0,49

-0,49

-0,49

-0,49

-0,49

0,26

4,02

-0,49

-0,49

-0,49

-0,49

-0,49

-0,49

-0,49

2,85

-0,49

2,74

-0,04

-0,49

-0,49

0,66

1.2.2022

28.2.2022

-0,49

-0,49

0,00

-0,49

3,29

-0,49

-0,03

-0,49

-0,49

-0,49

-0,49

-0,49

0,26

3,17

-0,49

-0,49

-0,49

-0,49

-0,49

-0,49

-0,49

2,04

-0,49

2,74

-0,05

-0,49

-0,49

0,66

1.1.2022

31.1.2022

-0,49

-0,49

0,00

-0,49

2,49

-0,49

-0,01

-0,49

-0,49

-0,49

-0,49

-0,49

0,26

2,38

-0,49

-0,49

-0,49

-0,49

-0,49

-0,49

-0,49

1,21

-0,49

2,27

-0,03

-0,49

-0,49

0,51

---

(1)  OJ L 140, 30.4.2004, p. 1

---